Date published: 2025-10-25

1-800-457-3801

SCBT Portrait Logo
Seach Input

WFDC9 Inhibitors

WFDC9 inhibitors are a class of chemical compounds that specifically target and inhibit the activity of the WFDC9 protein, which is part of the whey acidic protein (WAP) domain family. WFDC9 contains a conserved WAP domain, known for its involvement in regulating protease activity. Proteins containing WAP domains, such as WFDC9, are often associated with the inhibition of serine proteases, which play essential roles in various biological processes, including tissue remodeling, immune responses, and maintaining homeostasis. By inhibiting WFDC9, these compounds can modulate the protein's ability to regulate protease activity, thus influencing proteolytic pathways that are critical to cellular function and structural integrity.

The molecular mechanism by which WFDC9 inhibitors operate often involves the binding of the inhibitor to the WAP domain of WFDC9, preventing its interaction with target proteases. This inhibition disrupts the regulatory control that WFDC9 exerts over protease activity, leading to changes in the proteolytic environment within cells and tissues. Additionally, WFDC9 inhibitors may affect other pathways related to protein processing and degradation, as WFDC9 is thought to interact with multiple proteolytic systems. Researchers utilize these inhibitors to study the precise role of WFDC9 in biological processes, particularly in relation to its function in protease inhibition. By selectively targeting WFDC9, scientists can explore how changes in protease regulation influence cellular behaviors such as migration, adhesion, and extracellular matrix maintenance, which are critical for understanding the broader implications of protease control in biological systems.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

An mTOR inhibitor, impacting various cellular processes that might intersect with WFDC9's function.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

A phosphoinositide 3-kinases (PI3K) inhibitor, potentially altering cellular signaling pathways affecting WFDC9.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$63.00
$241.00
136
(2)

A MEK inhibitor, potentially affecting the ERK/MAPK pathway, which could indirectly influence WFDC9 activity.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$88.00
$342.00
284
(5)

Inhibits p38 MAP kinase, possibly altering signaling pathways relevant to WFDC9's function.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

A JNK inhibitor, potentially modifying signaling pathways indirectly affecting WFDC9.

Bafilomycin A1

88899-55-2sc-201550
sc-201550A
sc-201550B
sc-201550C
100 µg
1 mg
5 mg
10 mg
$96.00
$250.00
$750.00
$1428.00
280
(6)

Inhibits V-ATPase, potentially impacting endosomal-lysosomal functioning, influencing WFDC9 indirectly.

Chloroquine

54-05-7sc-507304
250 mg
$68.00
2
(0)

Known to affect autophagy and lysosomal function, which might indirectly influence WFDC9.

Autophagy Inhibitor, 3-MA

5142-23-4sc-205596
sc-205596A
50 mg
500 mg
$56.00
$256.00
113
(3)

An autophagy inhibitor, potentially impacting WFDC9 indirectly.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$66.00
$219.00
$417.00
97
(3)

A potent PI3K inhibitor, potentially affecting WFDC9 activity through intracellular signaling pathways.

Y-27632, free base

146986-50-7sc-3536
sc-3536A
5 mg
50 mg
$182.00
$693.00
88
(1)

A ROCK inhibitor, potentially influencing cytoskeletal dynamics relevant to WFDC9's function.